Literature DB >> 16931823

The costs of introducing a malaria vaccine through the expanded program on immunization in Tanzania.

Guy Hutton1, Fabrizio Tediosi.   

Abstract

This report presents an approach to costing the delivery of a malaria vaccine through the expanded program on immunization (EPI), and presents the predicted cost per dose delivered and cost per fully immunized child (FIC) in Tanzania, which are key inputs to the cost-effectiveness analysis. The costs included in the analysis are those related to the purchase of the vaccine taking into account the wastage rate; the costs of distributing and storing the vaccine at central, zonal, district, and facility level; those of managing the vaccination program; the costs of delivery at facility level (including personnel, syringes, safety boxes, and waste management); and those of additional training of EPI personnel and of social mobilization activities. The average cost per FIC increases almost linearly from US 4.2 dollars per FIC at a vaccine price of US 1 dollars per dose to US 31.2 dollars at vaccine price of US 10 dollars per dose. The marginal cost is approximately 5% less than the average cost. Although the vaccine price still determines most of the total delivery costs, the analysis shows that other costs are relevant and should be taken into account before marketing the vaccine and planning its inclusion into the EPI.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16931823     DOI: 10.4269/ajtmh.2006.75.119

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  19 in total

1.  Comparative cost models of a liquid nitrogen vapor phase (LNVP) cold chain-distributed cryopreserved malaria vaccine vs. a conventional vaccine.

Authors:  Cristina Reyes Garcia; Fatuma Manzi; Fabrizio Tediosi; Stephen L Hoffman; Eric R James
Journal:  Vaccine       Date:  2012-11-10       Impact factor: 3.641

Review 2.  Current state and challenges in developing oral vaccines.

Authors:  Julia E Vela Ramirez; Lindsey A Sharpe; Nicholas A Peppas
Journal:  Adv Drug Deliv Rev       Date:  2017-04-22       Impact factor: 15.470

3.  Safety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial.

Authors:  Pedro Aide; John J Aponte; Montse Renom; Tacilta Nhampossa; Jahit Sacarlal; Inacio Mandomando; Quique Bassat; Maria Nélia Manaca; Amanda Leach; Marc Lievens; Johan Vekemans; Marie-Claude Dubois; Christian Loucq; W Ripley Ballou; Joe Cohen; Pedro L Alonso
Journal:  PLoS One       Date:  2010-11-04       Impact factor: 3.240

4.  The use of cost-effectiveness analysis for pediatric immunization in developing countries.

Authors:  Cindy Low Gauvreau; Wendy J Ungar; Jillian Clare Köhler; Stanley Zlotkin
Journal:  Milbank Q       Date:  2012-12       Impact factor: 4.911

5.  From strategy development to routine implementation: the cost of Intermittent Preventive Treatment in Infants for malaria control.

Authors:  Fatuma Manzi; Guy Hutton; Joanna Schellenberg; Marcel Tanner; Pedro Alonso; Hassan Mshinda; David Schellenberg
Journal:  BMC Health Serv Res       Date:  2008-07-31       Impact factor: 2.655

6.  Costing RTS,S introduction in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and Uganda: A generalizable approach drawing on publicly available data.

Authors:  Katya Galactionova; Melanie Bertram; Jeremy Lauer; Fabrizio Tediosi
Journal:  Vaccine       Date:  2015-10-28       Impact factor: 3.641

7.  Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP.

Authors:  Tommy Rampling; Katie J Ewer; Georgina Bowyer; Nick J Edwards; Danny Wright; Saranya Sridhar; Ruth Payne; Jonathan Powlson; Carly Bliss; Navin Venkatraman; Ian D Poulton; Hans de Graaf; Diane Gbesemete; Amy Grobbelaar; Huw Davies; Rachel Roberts; Brian Angus; Karen Ivinson; Rich Weltzin; Bebi-Yassin Rajkumar; Ulrike Wille-Reece; Cynthia Lee; Chris Ockenhouse; Robert E Sinden; Stephen C Gerry; Alison M Lawrie; Johan Vekemans; Danielle Morelle; Marc Lievens; Ripley W Ballou; David J M Lewis; Graham S Cooke; Saul N Faust; Sarah Gilbert; Adrian V S Hill
Journal:  NPJ Vaccines       Date:  2018-10-09       Impact factor: 7.344

8.  Simulation of the cost-effectiveness of malaria vaccines.

Authors:  Fabrizio Tediosi; Nicolas Maire; Melissa Penny; Alain Studer; Thomas A Smith
Journal:  Malar J       Date:  2009-06-08       Impact factor: 2.979

9.  Modeling the public health impact of malaria vaccines for developers and policymakers.

Authors:  Julia K Nunes; Vicky Cárdenas; Christian Loucq; Nicolas Maire; Thomas Smith; Craig Shaffer; Kårstein Måseide; Alan Brooks
Journal:  BMC Infect Dis       Date:  2013-07-01       Impact factor: 3.090

10.  Sustainable manufacture of insect repellents derived from Nepeta cataria.

Authors:  Gregory S Patience; Ginette Karirekinyana; Federico Galli; Nicolas A Patience; Cariton Kubwabo; Guy Collin; Jean Claude Bizimana; Daria C Boffito
Journal:  Sci Rep       Date:  2018-02-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.